To assess and evaluate the safety of octaplas™ in comparison to standard plasma product
(e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of
thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange,
with a special emphasis on the occurrence of thromboembolic events (TEEs).